Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$13.18

0.06 (0.46%)

04:47
10/07/16
10/07
04:47
10/07/16
04:47

Exelixis announces results for cabozantinib phase 1 combination trial

Exelixis announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors. The findings will be presented during a poster discussion session on October 9 at the European Society for Medical Oncology 2016 Congress, which is being held in Copenhagen, October 7-11. "The treatment landscape for advanced, intractable cancers such as metastatic urothelial carcinoma is continuously evolving and the use of combination therapies may improve outcomes for patients in need of new options," said Andrea Apolo, M.D., Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, the principal investigator of the trial. "Our previous correlative studies have demonstrated that cabozantinib has immunomodulatory properties that may counteract tumor-induced immunosuppression, providing the rationale for this trial.1,2 These promising early stage clinical findings support further investigation of cabozantinib in combination with nivolumab in a number of genitourinary tumors." Between July 2015 and September 2016, 24 patients were accrued with metastatic urothelial carcinoma, urachal adenocarcinoma, squamous cell carcinoma of the bladder or urethra, germ cell tumor, castration-resistant prostate cancer, renal cell carcinoma, or trophoblastic tumor and were treated in Part I of the study, which evaluated the combination of cabozantinib and nivolumab at four dose levels. The median number of prior systemic therapies was 3, and 10 patients had received 4 or more prior therapies. The objective response rate was 43 percent among the 23 patients who were evaluable for response, with one complete response and nine partial responses. Four of six patients with urothelial cancer achieved a response. The recommended doses for the ongoing expansion cohorts were determined to be cabozantinib at 40 mg daily and nivolumab at 3 mg/kg once every 2 weeks. Part II of the phase 1 trial examining the use of the triplet combination of cabozantinib, nivolumab, and ipilimumab is also ongoing.

  • 07

    Oct

  • 10

    Oct

  • 10

    Oct

EXEL Exelixis
$13.18

0.06 (0.46%)

08/04/16
STFL
08/04/16
NO CHANGE
STFL
Exelixis price target raised to $12 from $10 at Stifel
Stifel analyst Stephen Willey raised his price target on Exelixis after the company reported significantly better than expected Cabometyx and residual/off-label Cometriq sales into the newly launched indication of refractory renal cell carcinom. Willey expects the results to improve investors' confidence towards the company's growth outlook, and he says that anticipation of front-line CABOSUN results places a near-term floor on the stock. The analyst keeps a Buy rating on the shares.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Exelixis selloff overdone, says Leerink
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.

TODAY'S FREE FLY STORIES

ATVI

Activision Blizzard

$45.08

-0.15 (-0.33%)

10:41
02/24/17
02/24
10:41
02/24/17
10:41
Options
Activision short-term calls active as shares tick higher »

Activision short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DOC

Physicians Realty Trust

$20.01

0.1 (0.50%)

10:40
02/24/17
02/24
10:40
02/24/17
10:40
Syndicate
Breaking Syndicate news story on Physicians Realty Trust »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

10:39
02/24/17
02/24
10:39
02/24/17
10:39
Conference/Events
CLSA technology/internet analyst holds an analyst/industry conference call »

Technology Analyst James…

RY

Royal Bank of Canada

$74.47

-0.41 (-0.55%)

10:37
02/24/17
02/24
10:37
02/24/17
10:37
Periodicals
RBC places Asia wealth business under review, Reuters reports »

Royal Bank of Canada has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SB

Safe Bulkers

$1.38

0.009 (0.66%)

10:36
02/24/17
02/24
10:36
02/24/17
10:36
Upgrade
Safe Bulkers rating change  »

Safe Bulkers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 22

    Mar

STX

Seagate

$47.39

0.04 (0.08%)

10:36
02/24/17
02/24
10:36
02/24/17
10:36
Options
Seagate put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

10:35
02/24/17
02/24
10:35
02/24/17
10:35
General news
The 3.7% U.S. January new home sales bounce »

The 3.7% U.S. January new…

SQ

Square

$17.23

0.075 (0.44%)

, TEX

Terex

$29.53

-0.38 (-1.27%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

SQ

Square

$17.23

0.075 (0.44%)

TEX

Terex

$29.53

-0.38 (-1.27%)

AERI

Aerie Pharmaceuticals

$44.25

-0.2 (-0.45%)

CLSD

Clearside Biomedical

$6.90

-0.29 (-4.03%)

PSTB

Park Sterling Bank

$12.07

-0.03 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 07

    Mar

  • 21

    Mar

  • 21

    Mar

  • 15

    May

HPE

HP Enterprise

$22.46

-2.205 (-8.94%)

, W

Wayfair

$38.32

-0.265 (-0.69%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

HPE

HP Enterprise

$22.46

-2.205 (-8.94%)

W

Wayfair

$38.32

-0.265 (-0.69%)

RIG

Transocean

$14.06

-0.25 (-1.75%)

GT

Goodyear Tire

$35.50

-0.45 (-1.25%)

JACK

Jack in the Box

$96.70

-6.9 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$13.44

-0.25 (-1.83%)

, AMCX

AMC Networks

$59.84

2.34 (4.07%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

WEN

Wendy's

$13.44

-0.25 (-1.83%)

AMCX

AMC Networks

$59.84

2.34 (4.07%)

CHK

Chesapeake

$5.81

0.055 (0.96%)

INTU

Intuit

$120.70

1.27 (1.06%)

HP

Helmerich & Payne

$68.53

-0.24 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MBLY

Mobileye

$46.54

-1.6 (-3.32%)

, NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Hot Stocks
Citron closes NVIDIA short, shifts focus to Mobileye »

Andrew Left's Citron…

MBLY

Mobileye

$46.54

-1.6 (-3.32%)

NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

  • 20

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
General news
Michigan sentiment slipped to an upwardly-revised 96.3 »

Michigan sentiment…

ELNK

EarthLink

$5.85

0.04 (0.69%)

, WIN

Windstream

$7.29

0.07 (0.97%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Windstream to host special shareholder meeting »

Virtual Special…

ELNK

EarthLink

$5.85

0.04 (0.69%)

WIN

Windstream

$7.29

0.07 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Wells Fargo housing analyst holds an analyst/industry conference call »

Senior Housing Analyst…

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
UBS pharma and medical devices analysts hold an analyst/industry conference call »

Major & Specialty…

JNJ

Johnson & Johnson

$122.19

1.2901 (1.07%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Johnson & Johnson hs a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
CLSA financial tech analyst holds an analyst/industry conference call »

Financial Technology…

CLVS

Clovis

$57.71

-3.48 (-5.69%)

10:22
02/24/17
02/24
10:22
02/24/17
10:22
Hot Stocks
Clovis reports allegations of misconduct, which it calls 'unfounded' »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$5.85

0.095 (1.65%)

10:21
02/24/17
02/24
10:21
02/24/17
10:21
Options
Renewed interest in Chesapeake Apr 7 calls »

Renewed interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

10:20
02/24/17
02/24
10:20
02/24/17
10:20
General news
Treasury Action: yields rebounded slightly »

Treasury Action: yields…

WIN

Windstream

$7.29

0.07 (0.97%)

, ELNK

EarthLink

$5.85

0.04 (0.69%)

10:20
02/24/17
02/24
10:20
02/24/17
10:20
Conference/Events
EarthLink to host special shareholder meeting »

Special Shareholder…

WIN

Windstream

$7.29

0.07 (0.97%)

ELNK

EarthLink

$5.85

0.04 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

MBLY

Mobileye

$46.81

-1.335 (-2.77%)

10:19
02/24/17
02/24
10:19
02/24/17
10:19
Hot Stocks
Breaking Hot Stocks news story on Mobileye »

Citron sees Mobileye…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

$NSD

NASDAQ Market Internals

10:17
02/24/17
02/24
10:17
02/24/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$23.48

-0.27 (-1.14%)

10:16
02/24/17
02/24
10:16
02/24/17
10:16
Options
Micron put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 09

    Mar

  • 20

    Mar

  • 23

    Mar

$NYE

NYSE Market Internals

10:16
02/24/17
02/24
10:16
02/24/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.